Feedback / Questions
laflunimus (AP-325) - Algiax
https://www.prnewswire.com/news-releases/algiax-pharmaceuticals-expands-phase-2a-study-with-lead-candidate-ap-325-in-chronic-neuropathic-pain-with-12-new-clinical-sites-in-belgium-and-france-302110636.html
Apr 11, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next